Lantern Pharma Spins Out Open-Medicine AI to Commercialize Its Multi-Agent AI Co-Scientist Platform
核心洞察
Lantern Pharma formally created Open-Medicine AI (搜索) (OMAI) as a wholly-owned subsidiary to commercialize its withZeta.ai (搜索) multi-agent AI platform, with plans for external funding and a potential public listing.
OMAI executed commercial licensing agreements granting access to Lantern's withZeta.ai (搜索)-related models, data, algorithms, and personnel, positioning it for independent growth across oncology and broader disease areas.
The global AI drug discovery and development market is projected to exceed $10 billion by 2030, with oncology representing the largest therapeutic segment and compound annual growth rates above 30 percent.
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, announced the formal creation of Open-Medicine AI (搜索) (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which received Lantern Pharma Board approval, are consistent with the framework outlined in Lantern's most recent registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist platform previously launched as withZeta.ai (搜索).
"The creation of Open-Medicine AI (搜索) and the execution of these licensing agreements mark a significant milestone," said Panna Sharma, President and CEO of Lantern Pharma and Founder of Open-Medicine AI. "withZeta.ai (搜索) demonstrated that a true multi-agentic co-scientist — specialized agents working in coordinated intelligence rather than a single model answering isolated questions — can dramatically compress research timelines and reduce the cost of generating hardened, actionable scientific insights. Open-Medicine AI takes that proven foundation and gives it the corporate structure, commercial licenses, and operational focus needed to scale across oncology and into additional complex disease areas."
A Strategic Evolution of withZeta.ai
The Open-Medicine AI (搜索) multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai (搜索) and is expanding into additional disease areas and modalities. OMAI will continue to advance the multi-agentic architecture, first proven in oncology and rare cancer research, while expanding its application across broader disease areas. The formation of the entity and the licensing arrangements position OMAI for independent growth, while expanding value creation opportunities and preserving strategic alignment with Lantern Pharma's clinical programs and shareholders.
OMAI inherits the full multi-agentic system originally commercialized as withZeta.ai (搜索), including coordinated specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers and translational science, clinical oncology, and general research. The platform also includes three research modes (Explorer, Investigator, Reporter) supporting rapid exploration through deep multi-source investigation to structured reporting, as well as proprietary rare-cancer knowledge bases and ontologies covering hundreds of disease entities, biomarkers, clinical trials, and literature.
Market Opportunity and Competitive Landscape
The global market for AI-enabled drug discovery and development tools is projected to exceed $10 billion by 2030, with oncology representing the largest therapeutic segment and compound annual growth rates above 30 percent. The underlying need is structural: traditional drug development remains slow, expensive, and poorly suited to the hundreds of rare and complex diseases that lack commercial scale under conventional models.
At the same time, major general-purpose AI companies — including Anthropic and OpenAI — have publicly signaled or begun developing platforms and tools aimed at scientific discovery and drug development. While general models excel at broad reasoning and language, domain-specific multi-agentic systems grounded in curated ontologies, domain-specific computational tools, and disease-area expertise are required to deliver the precision, auditability, and scientific rigor demanded by drug development.
OMAI is positioned at this intersection, combining specialized agent roles, recursive investigation modes, living knowledge graphs, and production tools including blood-brain barrier prediction, multi-omic analytics via ZetaOmics, and generative chemistry capabilities. Its architecture is designed not merely to retrieve information but to generate, stress-test, and harden insights in a manner that mirrors how expert scientific teams actually work.
AI Centers of Excellence in Dallas and Bengaluru
In the first quarter of 2026, Lantern established and staffed an AI Center of Excellence in Bengaluru, India. This center will serve as a core operational hub accelerating the development, refinement, and scaling of the Open-Medicine platform. The Bengaluru team will bring additional specialized talent to the existing team in Dallas, where Lantern is also headquartered. Both sites will focus on functional enhancements in multi-agent systems, computational biology modeling, knowledge engineering, and large-scale scientific curation.
Financial Position and Financing
The May 2026 registered direct financing of Lantern Pharma was led by Empery Asset Management (搜索), LP and also included an existing institutional healthcare investor and Lantern Board members. Mr. Ryan Lane, CIO and founder of Empery Asset Management, stated, "At Empery, we continue to be impressed by the relevance and usefulness of the insights and results generated by withZeta.AI (搜索)'s co-scientist platform. Among the various enterprise level agentic AI toolings we use, withZeta.AI continues to be our preferred platform for AI-assisted biopharma due diligence and research."
Lantern Pharma completed a $4.4 million registered direct offering in May 2026, with a concurrent private placement of warrants. Cash, cash equivalents, and marketable securities as of June 30, 2026 totaled $7.4 million, down from $10.1 million at year-end 2025. R&D expenses fell 42% year-over-year to $1.8 million, while G&A expenses rose 8% to $1.7 million.
Clinical Pipeline Context
Lantern Pharma continues to advance an AI-driven oncology pipeline with three clinical-stage candidates — LP-300, LP-184 (zirdafulven), and LP-284 — and an ADC program targeting 11 therapeutic areas, with multiple clinical trials and regulatory clearances in the US and Europe. Key milestones include EMA clearance for the LP-184 bladder cancer (搜索) trial, FDA clearance for LP-184 in triple-negative breast cancer (搜索), and an expanded patent estate.
"Open-Medicine AI (搜索) is built to change how medicines are discovered and developed globally, and as a separate company, to pursue dedicated funding and a valuation path distinct from Lantern's clinical activity and operations," said Panna Sharma, CEO and President of Lantern Pharma.